Metastatic colorectal cancer
Adult: As adjuvant therapy with FOLFIRI (irinotecan, folinic acid, fluorouracil) in patients with disease progression on, or after, or prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine: 8 mg/kg via infusion over 1 hour every 2 weeks prior to FOLFIRI administration. Continue until disease progression or unacceptable toxicity occurs. In case of toxicity, omit dose/s or modify according to product literature.
Intravenous
Advanced gastric carcinoma, Gastro-oesophageal junction adenocarcinoma
Adult: As monotherapy in patients with disease progression on or after fluoropyrimidine or platinum-based chemotherapy: 8 mg/kg via infusion over 1 hour every 2 weeks. As adjuvant therapy with paclitaxel in patients with disease progression on, or after fluoropyrimidine or platinum-based chemotherapy: 8 mg/kg via infusion over 1 hour on days 1 and 15 of a 28-day cycle, prior to paclitaxel administration. Continue until disease progression or unacceptable toxicity occurs. In case of toxicity, omit dose/s or modify according to product literature.
Intravenous
Locally advanced non-small cell lung carcinoma, Metastatic non-small cell lung carcinoma
Adult: As adjuvant therapy with docetaxel in patients with disease progression on, or after platinum-based chemotherapy: 10 mg/kg via infusion over 1 hour on day 1 of a 21-day cycle, prior to docetaxel administration. Continue until disease progression or unacceptable toxicity occurs. In case of toxicity, omit dose/s or modify according to product literature.